Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...

Moderna's Q1 2022 financial performance was better than expected, but MRNA didn't raise full-year 2022 guidance. See if MRNA stock is a buy, sell, or hold.

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years down the road, potentially benefit from a huge biotech growth story.

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Moderna (NASDAQ: MRNA) was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion ...

Overall, the performance of MRNA stock with respect to the index has been quite volatile. Returns for the stock were 143% in 2021, -29% in 2022, and -45% in 2023.

Moderna updated FY21 revenue guidance that came in below consensus estimates. The company also faces logistical issues. Find out if MRNA stock is a buy.

Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock dropped even further after lowering its expected revenue range for 2025 ...

A Look at Moderna's Recent Stock Price Performance Over the past month, the stock has seen a decline of 14.2% in its value, whereas the Zacks S&P 500 composite has posted a decrease of 0.5%.

We expect the Covid-19 shot to remain the primary driver of Moderna’s performance in 2022 as well. The global inoculation drive is still in the early stages, with the Bloomberg Vaccine Tracker ...